secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-277008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q3 operating expense down 26% vs Q1 2022; positive Phase 2 data for BBP-418 and infigratinib
--------------------------------------------------------------------------------

- Q3 operating costs $129.5M, down 26.2% from Q1 2022; net loss $137.3M vs $155.9M prior year.
- Cash, equivalents and marketable securities $558.3M, providing runway into 2024.
- BBP-418 12-month Phase 2: αDG glycosylation +0.21 at day 90, >75% creatine kinase reduction, no SAEs.
- Low-dose infigratinib Phase 2 Cohort 5 enrolled with no SAEs; AHV update in H1 2023, Phase 3 planned.
- First patient dosed in Phase 1/2 of BBP-398 plus Amgen's Lumakras for KRAS G12C; FDA Fast Track granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/0001193125-22-277008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/d389928d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-277008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer